Iovance Biotherapeutics, Inc. - Common Stock (IOVA)

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.

Tread carefully, but certain factors make this speculative biotech play stand out.

Iovance (IOVA) Q1 2026 Earnings Transcript

It could just as well drop by 50% -- or more -- over the next 12 months.

This oncology specialist has proven innovative abilities.

If you decide to invest in this company, it's probably best to start small.

Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.

Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized.

Iovance (IOVA) Q4 2025 Earnings Call Transcript

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

The company is studying its approved drug for many other indications.

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally stabilizing and corporate balance sheets bulging with record-breaking liquidity, the stage is set for a massive wave of

Don't get too excited about their prospects.

This juicy upside potential comes at a cost.

Iovance (IOVA) Q3 2025 Earnings Call Transcript

Iovance has a long way to go to get to a break-even point, but the company has been showing progress.

Wall Street may be overestimating these companies' potential.